BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31937618)

  • 21. The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis.
    Asjoe FT; Altintas S; Huizing MT; Colpaert C; Marck EV; Vermorken JB; Tjalma WA
    Breast J; 2007; 13(4):359-67. PubMed ID: 17593040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ipsilateral tumor recurrence risk in women with ductal carcinoma in situ: application of the Van Nuys Prognostic Index and the Memorial Sloan Kettering Cancer Center nomogram.
    Hashiba KA; Bahl M
    Breast Cancer Res Treat; 2023 Nov; 202(1):185-190. PubMed ID: 37518825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study.
    Sagara Y; Freedman RA; Vaz-Luis I; Mallory MA; Wong SM; Aydogan F; DeSantis S; Barry WT; Golshan M
    J Clin Oncol; 2016 Apr; 34(11):1190-6. PubMed ID: 26834064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS.
    Paszat L; Sutradhar R; Zhou L; Nofech-Mozes S; Rakovitch E
    Clin Breast Cancer; 2019 Feb; 19(1):35-46. PubMed ID: 30190195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast-conserving treatment for ductal carcinoma in situ: Impact of boost and tamoxifen on local recurrences.
    Cutuli B; Wiezzane N; Palumbo I; Barbieri P; Guenzi M; Huscher A; Borghesi S; Delva C; Iannone T; Vianello E; Rosetto ME; Aristei C
    Cancer Radiother; 2016 Jun; 20(4):292-8. PubMed ID: 27344537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
    Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
    Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prognostic index for ductal carcinoma in situ of the breast.
    Silverstein MJ; Lagios MD; Craig PH; Waisman JR; Lewinsky BS; Colburn WJ; Poller DN
    Cancer; 1996 Jun; 77(11):2267-74. PubMed ID: 8635094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization and treatment of local recurrence following breast conservation for ductal carcinoma in situ.
    Greenberg CC; Habel LA; Hughes ME; Nekhlyudov L; Achacoso N; Acton L; Schrag D; Jiang W; Edge S; Weeks JC; Punglia RS
    Ann Surg Oncol; 2014 Nov; 21(12):3766-73. PubMed ID: 24859938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
    Butt S; Butt T; Jirström K; Hartman L; Amini RM; Zhou W; Wärnberg F; Borgquist S
    Ann Surg Oncol; 2014 Sep; 21(9):2911-9. PubMed ID: 24777857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of hormonal status on outcome of ductal carcinoma in situ treated with breast-conserving surgery plus radiotherapy: Long-term experience from two large-institutional series.
    Meattini I; Saieva C; Bastiani P; Martella F; Francolini G; Lo Russo M; Paoletti L; Doria M; Desideri I; Terziani F; De Luca Cardillo C; Bendinelli B; Ciabatti C; Muntoni C; Tinacci G; Nori J; Smith H; Brancato B; Galli L; Sanchez LJ; Casella D; Bernini M; Orzalesi L; Carta GA; Bianchi S; Rossi F; Livi L
    Breast; 2017 Jun; 33():139-144. PubMed ID: 28384565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of predictive factors, particularly the Van Nuys index, of local recurrence in ductal carcinoma in situ of the breast: study of 166 cases with conservative treatment and review of the literature].
    Denoux Y; Marnay J; Crouet H; Boute V; Delozier T; Vie B; Chasle J
    Bull Cancer; 2001 Apr; 88(4):419-25. PubMed ID: 11371378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of care with regard to surgical choice and application of adjuvant radiation therapy for preinvasive and early stage breast cancer in rural Appalachia.
    Freeman AB; Huang B; Dragun AE
    Am J Clin Oncol; 2012 Aug; 35(4):358-63. PubMed ID: 21422902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term cosmesis after lumpectomy and brachytherapy in the management of carcinoma of the previously irradiated breast.
    Trombetta M; Julian TB; Werts DE; McWilliams W; Kim Y; Miften M; Parda D
    Am J Clin Oncol; 2009 Jun; 32(3):314-8. PubMed ID: 19451803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic classification of breast ductal carcinoma-in-situ.
    Silverstein MJ; Poller DN; Waisman JR; Colburn WJ; Barth A; Gierson ED; Lewinsky B; Gamagami P; Slamon DJ
    Lancet; 1995 May; 345(8958):1154-7. PubMed ID: 7723550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels.
    Evans MF; Vacek PM; Sprague BL; Stein GS; Stein JL; Weaver DL
    J Cell Biochem; 2020 Feb; 121(2):1736-1746. PubMed ID: 31595577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis.
    De Lorenzi F; Di Bella J; Maisonneuve P; Rotmensz N; Corso G; Orecchia R; Colleoni M; Mazzarol G; Rietjens M; Loschi P; Marcelli S; Veronesi P; Galimberti V
    Eur J Surg Oncol; 2018 Jul; 44(7):957-962. PubMed ID: 29759643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).
    Darvishian F; Ozerdem U; Adams S; Chun J; Pirraglia E; Kaplowitz E; Guth A; Axelrod D; Shapiro R; Price A; Troxel A; Schnabel F; Roses D
    Ann Surg Oncol; 2019 Oct; 26(10):3337-3343. PubMed ID: 31240590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 21-Gene Assay and Breast Cancer Mortality in Ductal Carcinoma In Situ.
    Rakovitch E; Sutradhar R; Nofech-Mozes S; Gu S; Fong C; Hanna W; Paszat L
    J Natl Cancer Inst; 2021 May; 113(5):572-579. PubMed ID: 33369631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.